Interleukin-2 Therapy of Metastatic Renal Cell Carcinoma-Predictors of Response

Seminars in Oncology

Volumn 33, Issue 5, 2006, Pages 583-587

  McDermott, David F ^a   Atkins, Michael B ^a  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; INTERLEUKIN 2;

ADULT RESPIRATORY DISTRESS SYNDROME; ARTICLE; CLINICAL TRIAL; DEATH; DRUG MEGADOSE; HUMAN; HYPOTENSION; KIDNEY CARCINOMA; METASTASIS; PREDICTION; PRIORITY JOURNAL; SIDE EFFECT; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; HUMANS; INTERLEUKIN-2; KIDNEY NEOPLASMS; PREDICTIVE VALUE OF TESTS; TUMOR MARKERS, BIOLOGICAL;

EID: 33749443423     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2006.06.004     Document Type: Article

References (32)

1. Linehan W.M., Bates S.E., and Yang J.C. Cancers of the kidney. In: DeVita Jr. V.T. (Ed). Cancer: Principles and Practice of Oncology. (ed 7). (2005), Lippincott Williams & Wilkins, Philadelphia, PA 1139-1167
2. Cohen H.T., and McGovern F.J. Renal-cell carcinoma. N Engl J Med 353 (2005) 2477-2490
3. Motzer R.J., Mazumdar M., Bacik J., et al. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol 17 (1999) 2530-2540
4. Yagoda A., Petrylak D., and Thompson S. Cytotoxic chemotherapy for advanced renal cell carcinoma. Urol Clin North Am 20 (1993) 303-314
5. Pyrhonen S., Salminen E., Lehtonen T., et al. Recombinant interferon alfa-2a with vinblastine vs. vinblastine alone in advanced renal cell carcinoma: A phase II study. J Clin Oncol 15 (1996) 244 (abstr)
6. Muss H.B., Costanzi J.J., Leavitt R., et al. Recombinant alfa interferon in renal cell carcinoma: A randomized trial of two routes of administration. J Clin Oncol 5 (1987) 286-291
7. Yang J.C., Haworth L., Sherry R.M., et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 349 (2003) 427-434
8. Motzer R.J., Michaelson M.D., Redman B.G., et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patient with metastatic renal cell carcinoma. J Clin Oncol 24 (2006) 16-24
9. Fyfe G., Fisher R.I., Rosenberg S.A., et al. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J Clin Oncol 13 (1995) 688-696
10. Fisher R.I., Rosenberg S.A., and Fyfe G. Long-term survival update for high-dose recombinant Interleukin-2 in patients with renal cell carcinoma. Cancer J Sci Am 6 (2000) S55-S57
11. Rosenberg S.A., Yang J.C., White D.E., et al. Durability of complete responses in patients with metastatic cancer treated with high-dose interleukin-2. Identification of the antigens mediating response. Ann Surg 228 (1998) 307-319
12. Negrier S., Lasset C., Douillard J.-Y., et al. Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. N Engl J Med 338 (1998) 1272-1278
13. Yang J.C., Sherry R.M., Stienberg S.M., et al. A three-arm randomized comparison of high and low dose intravenous and subcutaneous interleukin-2 in the treatment of metastatic renal cancer. J Clin Oncol 21 (2003) 3127-3132
14. Sleijfer D.T., Janssen R.J., Buter J., et al. Phase II study of subcutaneous interleukin-2 in unselected patients with advanced renal cell cancer on a outpatient basis. J Clin Oncol 10 (1992) 1119-1123
15. McDermott D.F., Regan M.M., Clark J.I., et al. A randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J Clin Oncol 23 (2005) 133-141
16. Besana C., Borri A., Bucci E., et al. Treatment of advanced renal cell cancer with sequential intravenous recombinant interleukin-2 and subcutaneous α-interferon. Eur J Cancer 9 (1994) 1292-1298
17. Rosenberg S.A., Lotze M.T., Yang J.C., et al. Combination therapy with interleukin-2 and alpha-interferon for the treatment of patients with advanced cancer. J Clin Oncol 7 (1989) 1863-1874
18. Figlin R., Gitlitz B., Franklin J., et al. Interleukin-2-based immunotherapy for the treatment of metastatic renal cell carcinoma: An analysis of 203 consecutively treated patients. Cancer J Sci Am 3 (1997) S92-S97
19. Leibovich B.C., Han K.R., Bui M.H., et al. Scoring algorithm to predict survival after nephrectomy and immunotherapy in patients with metastatic renal cell carcinoma: A stratification tool for prospective clinical trials. Cancer 98 (2003) 2566-2575
20. Royal R.E., Steinberg S.M., Krouse R.S., et al. Correlates of response to IL-2 therapy in patients treated for metastatic renal cancer and melanoma. Cancer J Sci Am 2 (1996) 91-94
21. Atkins M.B., Mier J.W., Parkinson D.R., et al. Hypothyroidism after treatment with interleukin-2 and lymphokine-activated killer cells. N Engl J Med 318 (1988) 1557-1563
22. Fumagalli L.A., Vinke J., Hoff W., et al. Lymphocyte counts independently predict overall survival in advanced cancer patients: A biomarker for IL-2 immunotherapy. J Immunother 26 (2003) 394-402
23. West W.H., Tauer K.W., Yanelli J.R., et al. Constant-infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer. N Engl J Med 316 (1987) 898-905
24. Janik J.E., Sznol M., Urba W.J., et al. Erythropoietin production. A potential marker for interleukin-2/interferon-responsive tumors. Cancer 72 (1993) 2656-2659
25. Negrier S., Caty A., Lesimple T., et al. Treatment of patients with metastatic renal carcinoma with a combination of subcutaneous interleukin-2 and interferon alfa with or without fluorouracil. J Clin Oncol 18 (2000) 4009-4015
26. Cangiano T., Liao J., Naitoh J., et al. Sarcomatoid renal cell carcinoma: Biologic behavior, prognosis, and response to combined surgical resection and immunotherapy. J Clin Oncol 17 (1999) 523-528
27. Motzer R.J., Bacil J., Mariani T., et al. Treatment outcome and survival associated with metastatic renal cell carcinoma of non-clear-cell histology. J Clin Oncol 20 (2002) 2376-2381
28. Upton M.P., Parker R.A., Youmans A., et al. Renal cell carcinoma: Histologic predictors of cytokine response. J Immunother 28 (2005) 488-495
29. Bui M.H.T., Seligson D., Han K., et al. Carbonic anhydrase IX is an independent predictor of survival in advanced renal cell carcinoma: Implications for prognosis and therapy. Clin Cancer Res 9 (2003) 802-811
30. Atkins M., Regan M., McDermott D., et al. Carbonic anhydrase IX expression predicts outcome of interleukin-2 therapy for renal cancer. Clin Cancer Res 11 (2005) 3714-3721
31. Pantuck A.J., Fang Z., Liu X., et al. Gene expression and tissue microarray analysis of interleukin-2 complete responders in patients with metastatic renal cell carcinoma. J Clin Oncol 23 16S (2005) 386s (abstr 4535)
32. Dutcher J. Current status of interleukin-2 therapy for metastatic renal cell carcinoma and metastatic melanoma. Oncology 16 (2002) 4-10